Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference
Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference being held virtually on May 21 and 22, 2024. The Company will host a fireside chat at 3:00 pm ET on May 21, 2024.
圣地亚哥，2024年5月14日（GLOBE NEWSWIRE）——Belite Bio, Inc.（纳斯达克股票代码：BLTE）是一家临床阶段的生物制药药物开发公司，专注于推进针对医疗需求未得到满足的退行性视网膜疾病的新疗法，今天宣布，执行管理团队将参与Benchmark的4项计划第四 年度医疗保健众议院电话会议将于2024年5月21日和22日以虚拟方式举行。该公司将于美国东部时间2024年5月21日下午3点举办炉边谈话。
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite's lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at .
关于 Belite Bio
Belite Bio是一家临床阶段的生物制药药物开发公司，专注于推进针对严重未满足医疗需求的退行性视网膜疾病的新疗法，例如1型Stargardt病（STGD1）和晚期干性年龄相关性黄斑变性（AMD）的地理萎缩（GA），以及特定的代谢性疾病。Belite的主要候选药物Tinlarebant是一种旨在减少眼内毒素积累的口服疗法，目前正在对青少年 STGD1 受试者进行三期研究（DRAGON）和一项2/3期研究（DRAGON II）以及一项针对GA受试者的3期研究（PHOENIX）进行评估。欲了解更多信息，请在推特、Instagram、领英、脸书上关注我们，或访问我们的网站。
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
媒体和投资者关系联系人：
詹妮弗·伍
ir@belitebio.com
Julie Fallon
belite@argotpartners.com
朱莉·法伦
belite@argotpartners.com
译文内容由第三方软件翻译。